{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:44:08Z","timestamp":1790390648019,"version":"4.1.0"},"reference-count":106,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>T-cell\u2013engaging bispecific antibodies (BsAbs) have transformed the treatment landscape for multiple hematologic malignancies and are under investigation in the frontline setting, within combination regimens, and for nonmalignant diseases. However, their increasing use has revealed new patterns of immune suppression and infectious complications that differ from other treatment modalities, including chimeric antigen receptor T-cell therapy. Notably, infections are frequent and represent the principal cause of nonrelapse mortality. These risks with repeated BsAb dosing arise from multifactorial mechanisms, including B-cell or plasma-cell aplasia, hypogammaglobulinemia, and early cytopenias. Additional contributors such as T-cell exhaustion, cytokine-directed immune modulation, and disease-related immunodeficiency, further compound infection risk. The result is a dynamic and cumulative impairment of host immunity that evolves over the course of therapy. In this \u201cHow I Treat\u201d article, we provide a practical, phase-based framework for preventing and managing infections in patients receiving BsAbs for non-Hodgkin lymphoma or multiple myeloma. Our review includes pretreatment evaluation, the period of active therapy, and long-term follow-up. Using representative cases, we highlight strategies for infectious disease screening, antimicrobial prophylaxis, immunoglobulin supplementation, vaccination, and other supportive care practices. Our aim is to equip clinicians with an evidence-informed and pragmatic framework for mitigating BsAb-related infection risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032298","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:02:29Z","timestamp":1778605349000},"page":"927-938","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"first","affiliation":[{"name":"1Department of Medicine III, Hematology\/Oncology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of Washington, Seattle, WA"},{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-9834","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of Washington, Seattle, WA"},{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"5Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2026082011214236600_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2024.11.012","article-title":"Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives","volume":"25","author":"Waldschmidt","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026082011214236600_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives","volume":"14","author":"Abou Dalle","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026082011214236600_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/hematology.2025000740","article-title":"Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma","volume":"2025","author":"Iacoboni","year":"2025","journal-title":"Hematology"},{"issue":"1","key":"2026082011214236600_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026082011214236600_bib5","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther"},{"issue":"16","key":"2026082011214236600_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026082011214236600_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2026082011214236600_bib8","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026082011214236600_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026082011214236600_bib10","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026082011214236600_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2025.2586082","article-title":"Balancing gains and pains: infections in the bispecific era","volume":"67","author":"Ibrahim","year":"2026","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026082011214236600_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-025-01393-8","article-title":"Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"15","author":"Jurgens","year":"2025","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026082011214236600_bib13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2026082011214236600_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2026082011214236600_bib15","doi-asserted-by":"crossref","first-page":"e70138","DOI":"10.1111\/tid.70138","article-title":"Cytomegalovirus infection after chimeric antigen receptor t-cell therapy or bispecific antibody treatment for hematologic malignancies","volume":"27","author":"Han","year":"2025","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"2026082011214236600_bib16","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/bloodadvances.2024015164","article-title":"The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy","volume":"9","author":"Kampouri","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026082011214236600_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"14","key":"2026082011214236600_bib18","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2026082011214236600_bib19","doi-asserted-by":"crossref","first-page":"ofae422","DOI":"10.1093\/ofid\/ofae422","article-title":"Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes","volume":"11","author":"Khawaja","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"2026082011214236600_bib20","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026082011214236600_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2026082011214236600_bib22","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1080\/10428194.2025.2540442","article-title":"Real-world infectious complications of CD3\/CD20 bispecific antibodies in relapsed\/refractory non-Hodgkin lymphoma","volume":"66","author":"Xiao","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2026082011214236600_bib23","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2026082011214236600_bib24","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026082011214236600_bib25","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1038\/s41467-026-71473-1","article-title":"Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response","volume":"17","author":"Ozog","year":"2026","journal-title":"Nat Commun."},{"key":"2026082011214236600_bib26","doi-asserted-by":"crossref","first-page":"101316","DOI":"10.1016\/j.blre.2025.101316","article-title":"Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: pathophysiology, clinical implications, management options, and future directions","volume":"74","author":"Wonnaparhown","year":"2025","journal-title":"Blood Rev"},{"issue":"13","key":"2026082011214236600_bib27","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026082011214236600_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"suppl 1","key":"2026082011214236600_bib29","article-title":"Hematotoxicity and immune deficits with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma [abstract]","volume":"146","author":"Tix","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026082011214236600_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2026082011214236600_bib31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026082011214236600_bib32","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbmt.2018.01.017","article-title":"Choosing wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group\u2019s list of 5 tests and treatments to question in blood and marrow transplantation","volume":"24","author":"Bhella","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2026082011214236600_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"2026082011214236600_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"2026082011214236600_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2026082011214236600_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","article-title":"IgG replacement in multiple myeloma","volume":"14","author":"Wonnaparhown","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026082011214236600_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026082011214236600_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1398-9995.2005.00756.x","article-title":"Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency","volume":"60","author":"Favre","year":"2005","journal-title":"Allergy"},{"issue":"suppl 6","key":"2026082011214236600_bib39","first-page":"S105","article-title":"Managing cost of care and healthcare utilization in patients using immunoglobulin agents","volume":"25","author":"Vaughan","year":"2019","journal-title":"Am J Manag Care"},{"issue":"3","key":"2026082011214236600_bib40","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1200\/OP.20.00312","article-title":"Changes in intravenous immunoglobulin usage for hypogammaglobulinemia after implementation of a stewardship program","volume":"17","author":"Derman","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"2026082011214236600_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"2026082011214236600_bib42","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/j.clml.2025.12.003","article-title":"European expert recommendations on teclistamab management for relapsed or refractory multiple myeloma","volume":"26","author":"Rodr\u00edguez-Otero","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026082011214236600_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","article-title":"Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"15","author":"Al Hadidi","year":"2025","journal-title":"Blood Cancer J"},{"issue":"10","key":"2026082011214236600_bib44","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.2025029572","article-title":"Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs","volume":"147","author":"Jelinek","year":"2026","journal-title":"Blood"},{"issue":"suppl 16","key":"2026082011214236600_bib45","article-title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study","volume":"41","author":"Mohty","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2026082011214236600_bib46","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026082011214236600_bib47","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2026082011214236600_bib48","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","article-title":"Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma","volume":"8","author":"Ludwig","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026082011214236600_bib49","first-page":"656","article-title":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","volume":"111","author":"Cani","year":"2026","journal-title":"Haematologica"},{"issue":"2","key":"2026082011214236600_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"2026082011214236600_bib51","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/bloodadvances.2025016291","article-title":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis","volume":"9","author":"van Besien","year":"2025","journal-title":"Blood Adv"},{"issue":"10301","key":"2026082011214236600_bib52","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"2026082011214236600_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"2026082011214236600_bib54","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2024015406","article-title":"Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders","volume":"9","author":"Serna","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026082011214236600_bib55","doi-asserted-by":"crossref","first-page":"35665","DOI":"10.1002\/cncr.35665","article-title":"Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1","volume":"131","author":"Cai","year":"2025","journal-title":"Cancer"},{"issue":"8","key":"2026082011214236600_bib56","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2026082011214236600_bib57","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026082011214236600_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026082011214236600_bib59","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","article-title":"Noncanonical and mortality-defining toxicities of CAR T cell therapy","volume":"31","author":"Rejeski","year":"2025","journal-title":"Nat Med"},{"issue":"22","key":"2026082011214236600_bib60","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"2026082011214236600_bib61","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.2025031744","article-title":"Immune biomarkers of increased infection risk in multiple myeloma","volume":"147","author":"Zabaleta","year":"2026","journal-title":"Blood"},{"issue":"1","key":"2026082011214236600_bib62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"24","key":"2026082011214236600_bib63","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026082011214236600_bib64","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/bloodadvances.2025017766","article-title":"Prognostic value of inflammation-based scores in r\/r LBCL patients treated with CD3xCD20 bispecific T-bell engagers","volume":"10","author":"Magno","year":"2026","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026082011214236600_bib65","article-title":"Evaluation of baseline CAR-hematotox scores to predict increased severe infection risk in patients with relapsed\/refractory follicular lymphoma treated with odronextamab [abstract]","volume":"144","author":"Matasar","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026082011214236600_bib66","article-title":"Evaluation of CAR-hematotox scoring as a predictor of infection risk following treatment with odronextamab (a CD20\u00d7CD3 bispecific antibody) in relapsed\/refractory diffuse large B-cell lymphoma [abstract]","volume":"144","author":"Matasar","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026082011214236600_bib67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2643-3230.BCD-25-0062","article-title":"Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy","volume":"7","author":"Frenking","year":"2026","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026082011214236600_bib68","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1002\/hem3.70062","article-title":"Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma","volume":"9","author":"Stock","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"2026082011214236600_bib69","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2026082011214236600_bib70","doi-asserted-by":"crossref","first-page":"e70224","DOI":"10.1002\/hem3.70224","article-title":"The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: results from magnetisMM-3","volume":"9","author":"Bahlis","year":"2025","journal-title":"Hemasphere"},{"issue":"6","key":"2026082011214236600_bib71","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"10","key":"2026082011214236600_bib72","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026082011214236600_bib73","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2026082011214236600_bib74","doi-asserted-by":"crossref","first-page":"e192927","DOI":"10.1172\/JCI192927","article-title":"Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy","volume":"135","author":"Duffy","year":"2025","journal-title":"J Clin Invest"},{"issue":"5","key":"2026082011214236600_bib75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtct.2025.02.019","article-title":"T cell immune response to influenza vaccination when administered prior to and following autologous chimeric antigen receptor-modified T cell therapy","volume":"31","author":"Kinoshita","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2026082011214236600_bib76","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/cid\/ciae291","article-title":"SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T-cell therapy: a prospective, multicenter, observational study","volume":"79","author":"Hill","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"724","key":"2026082011214236600_bib77","doi-asserted-by":"crossref","first-page":"eadh4529","DOI":"10.1126\/scitranslmed.adh4529","article-title":"T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19","volume":"15","author":"Zonozi","year":"2023","journal-title":"Sci Transl Med"},{"issue":"2","key":"2026082011214236600_bib78","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/bloodadvances.2025018225","article-title":"Vaccination during bispecific antibody treatment for myeloma","volume":"10","author":"Banerjee","year":"2026","journal-title":"Blood Adv"},{"issue":"2","key":"2026082011214236600_bib79","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/bloodadvances.2025018127","article-title":"Vaccination should not be forgotten in patients receiving immunoglobulin replacement therapy","volume":"10","author":"Einarsdottir","year":"2026","journal-title":"Blood Adv"},{"issue":"7","key":"2026082011214236600_bib80","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2026082011214236600_bib81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2026082011214236600_bib82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2026082011214236600_bib83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"2026082011214236600_bib84","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"23","key":"2026082011214236600_bib85","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2026082011214236600_bib86","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2026082011214236600_bib87","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2026082011214236600_bib88","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2026082011214236600_bib89","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026082011214236600_bib90","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","article-title":"Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"15","author":"Einarsdottir","year":"2025","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026082011214236600_bib91","article-title":"Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma [abstract]","volume":"146","author":"Razzo","year":"2025","journal-title":"Blood"},{"issue":"817","key":"2026082011214236600_bib92","doi-asserted-by":"crossref","first-page":"eadu9790","DOI":"10.1126\/scitranslmed.adu9790","article-title":"CAR T cell\u2013mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis","volume":"17","author":"Khelil","year":"2025","journal-title":"Sci Transl Med"},{"issue":"9","key":"2026082011214236600_bib93","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/bmt.2009.364","article-title":"Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant","volume":"45","author":"Cordonnier","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2026082011214236600_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbmt.2004.12.330","article-title":"Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation","volume":"11","author":"Antin","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2026082011214236600_bib95","first-page":"1","article-title":"General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Kroger","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"suppl 1","key":"2026082011214236600_bib96","article-title":"Updated results from a phase II study of vibecotamab, a CD3-CD123 bispecific T-Cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML [abstract]","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026082011214236600_bib97","article-title":"Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies [abstract]","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026082011214236600_bib98","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2026082011214236600_bib99","article-title":"Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed\/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: high complete responses seen in CAR-T-naive and CAR-T-exposed patients [abstract]","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"issue":"22","key":"2026082011214236600_bib100","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMc2502297","article-title":"BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy","volume":"392","author":"Zhang","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"2026082011214236600_bib101","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026082011214236600_bib102","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"10527","key":"2026082011214236600_bib103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(25)02515-2","article-title":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia","volume":"407","author":"Duque-Afonso","year":"2026","journal-title":"The Lancet"},{"issue":"3","key":"2026082011214236600_bib104","doi-asserted-by":"crossref","first-page":"e35738","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"2026082011214236600_bib105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"2026082011214236600_bib106","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1182\/bloodadvances.2022008338","article-title":"Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor\u2013modified T-cell therapy","volume":"7","author":"Gonzalez","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/8\/927\/2538255\/blood_bld-2025-032298-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/8\/927\/2538255\/blood_bld-2025-032298-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:24:01Z","timestamp":1787239441000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/8\/927\/568352\/How-I-prevent-infections-in-adults-receiving"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032298","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,20]]},"published":{"date-parts":[[2026,8,20]]}}}